Company intelligence / Profile preview

Sisioai Biomedical

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Sisioai Biomedical is a China-based biotechnology company focused on the discovery and development of innovative small molecule therapeutics. The company leverages advanced structure-based drug design (SBDD) and computational chemistry platforms to target challenging biological pathways in oncology and immunology. Sisioai aims to address significant unmet medical needs by developing high-potency, selective drug candidates for complex disease mechanisms. Currently, the company's pipeline is primarily in the discovery and pre-clinical stages of development.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeTargeted therapy
Industry: Biotech

Beyond the preview

Go deeper on Sisioai Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sisioai Biomedical.

Explore the full profile